Hennion & Walsh Asset Management Inc. Has $2 Million Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Hennion & Walsh Asset Management Inc. increased its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 19.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 23,794 shares of the medical instruments supplier's stock after buying an additional 3,852 shares during the quarter. Hennion & Walsh Asset Management Inc. owned about 0.11% of LeMaitre Vascular worth $1,996,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the business. Congress Asset Management Co. raised its holdings in shares of LeMaitre Vascular by 1.8% in the 4th quarter. Congress Asset Management Co. now owns 722,325 shares of the medical instruments supplier's stock worth $66,555,000 after purchasing an additional 13,009 shares during the period. Geode Capital Management LLC grew its stake in LeMaitre Vascular by 1.4% during the 4th quarter. Geode Capital Management LLC now owns 550,260 shares of the medical instruments supplier's stock valued at $50,711,000 after purchasing an additional 7,737 shares in the last quarter. Northern Trust Corp grew its stake in LeMaitre Vascular by 5.1% during the 4th quarter. Northern Trust Corp now owns 327,815 shares of the medical instruments supplier's stock valued at $30,205,000 after purchasing an additional 15,843 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in LeMaitre Vascular by 0.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 284,779 shares of the medical instruments supplier's stock valued at $26,240,000 after purchasing an additional 1,680 shares in the last quarter. Finally, Envestnet Asset Management Inc. grew its stake in LeMaitre Vascular by 7.0% during the 4th quarter. Envestnet Asset Management Inc. now owns 259,429 shares of the medical instruments supplier's stock valued at $23,904,000 after purchasing an additional 16,886 shares in the last quarter. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on LMAT. Wells Fargo & Company assumed coverage on LeMaitre Vascular in a research note on Thursday, February 13th. They set an "equal weight" rating and a $95.00 price objective for the company. Lake Street Capital lifted their target price on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Oppenheimer lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Finally, Barrington Research lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, LeMaitre Vascular presently has an average rating of "Hold" and an average target price of $97.83.

Insiders Place Their Bets

In other news, insider Trent G. Kamke sold 2,009 shares of the business's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total transaction of $164,979.08. Following the sale, the insider now directly owns 5,564 shares of the company's stock, valued at $456,915.68. The trade was a 26.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO George W. Lemaitre sold 4,399 shares of the company's stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $85.10, for a total value of $374,354.90. Following the transaction, the chief executive officer now directly owns 1,827,003 shares in the company, valued at $155,477,955.30. The trade was a 0.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 102,009 shares of company stock worth $8,721,836. 9.50% of the stock is owned by company insiders.

LeMaitre Vascular Price Performance

NASDAQ:LMAT traded up $0.73 during midday trading on Friday, reaching $84.13. 95,034 shares of the company traded hands, compared to its average volume of 168,421. LeMaitre Vascular, Inc. has a twelve month low of $71.42 and a twelve month high of $109.58. The firm has a market capitalization of $1.90 billion, a price-to-earnings ratio of 45.97, a price-to-earnings-growth ratio of 2.22 and a beta of 0.83. The company has a fifty day moving average price of $83.71 and a 200 day moving average price of $91.10.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.02). LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business had revenue of $59.87 million for the quarter, compared to analyst estimates of $57.61 million. During the same quarter last year, the firm posted $0.44 EPS. The company's revenue was up 12.0% compared to the same quarter last year. On average, equities research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, May 29th. Shareholders of record on Thursday, May 15th were given a dividend of $0.20 per share. The ex-dividend date was Thursday, May 15th. This represents a $0.80 dividend on an annualized basis and a yield of 0.95%. LeMaitre Vascular's dividend payout ratio (DPR) is presently 40.40%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.